GHRH and cancer: Growth hormone-releasing hormone antagonists suppress the in vivo growth of various experimental cancers such as prostatic (Zarandi et al, 2006; Stangelberger et al, 2007), mammary (Buchholz et al, 2007), ovarian (Chatzistamou et al, 2001), renal cell carcinomas (Halmos et al, 2000), small cell lung carcinomas (Hohla et al, 2006), pancreatic and colorectal carcinomas (Szepeshazi et al, 2000; Busto et al, 2002), endometrial (Engel et al, 2005), osteogenic sarcomas (Braczkowski et al, 2002) as well as malignant glioblastomas (Jaeger et al, 2005).